KRAS and neoplasm: In a PDAC murine model, the KRAS G12D reversible inhibitor, MRTX1133, when combined with CXCR1/2 inhibitor and anti-LAG3 and anti-41BB antibodies yielded complete tumor regression and prolonged survival in 36% of mice at 6 months [113].